← Back to Patent Explorer
US4474747A Expired / Lapsed US ⏱️ 0.0 years remaining

Process for increasing the tolerance of X-ray contrast media, and contrast media obtained thereby

Assignee: Guerbet SA
•
Filing: 1982-08-18
•
Granted: 1984-10-02
•
Expires: 2002-08-18
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract X-ray contrast media, for which the human body has a greater tolerance than that of contrast media comprising solely iodobenzene compounds, and an opacity of the same order of magnitude as the latter contrast media, comprise mixtures of benzene compounds nuclearly substituted with a plurality of iodine atoms and of benzene compounds nuclearly substituted with a plurality of bromine atoms, the bromobenzene compounds having the mole ratio from 1/2 to 2/1 to the iodobenzene compounds in the mixture.

Inventors

  • 👤 Ioana Dimo
  • 👤 Bruno Bonnemain
  • 👤 Jean C. Hardouin
  • 👤 Jean Lautrou

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 14:52
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/04; A61K49/0433; Y; Y10; Y10S; Y10S424/00; Y10S424/90

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 74 words
X-ray contrast media, for which the human body has a greater tolerance than that of contrast media comprising solely iodobenzene compounds, and an opacity of the same order of magnitude as said contrast media, comprising mixtures of benzene compounds nuclearly substituted with a plurality of iodine atoms and of benzene compounds nuclearly substituted with a plurality of bromine atoms, wherein the bromobenzene compounds represent from 1/2 to 2/1 (in moles) of the iodobenzene compounds.
Claim 2
Dependent Claim 74 words
X-ray contrast media, for which the human body has a greater tolerance than that of contrast media comprising solely iodobenzene compounds, and an opacity of the same order of magnitude as said contrast media, comprising mixtures of benzene compounds nuclearly substituted with a plurality of iodine atoms and of benzene compounds nuclearly substituted with a plurality of bromine atoms, wherein the bromobenzene compounds represent from 1/2 to 2/1 (in moles) of the iodobenzene compounds.
Claim 3
Dependent Claim 209 words
X-ray contrast media as claimed in claim 1, which contain mixtures of two or more of the following compounds, at least one of which is a bromo compound and at least another of which is an iodo compound: I--Compounds of the formula: ##STR99## in which: the substituents X are selected from I and Br, and Q 1 , Q 2 and Q 3 are pharmacologically acceptable groups, II--Compounds of the formula: ##STR100## in which: the substituents X are selected from I and Br, and Q 1 , Q 2 , Q 3 , Q 4 , Y 1 , Y 2 and P are pharmacologically acceptable groups, III--Compounds of the formula: ##STR101## in which: the substituents X are selected from I and Br, and Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Y 1 , Y 2 , Y 3 , Y 4 , P 1 and P 2 are pharmacologically acceptable groups, IV--Compounds of the formula: ##STR102## in which: the substituents X are selected from I and Br, and Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Q 6 , Y 1 , Y 2 , Y 3 and P are pharmacologically acceptable groups.
Claim 4
Dependent Claim 961 words
X-ray contrast media as claimed in claim 1, which contain mixtures of two or more of the following compounds, at least one of which is a bromo compound and at least another of which is a iodo compound: 1--compounds of the formula: ##STR103## in which: X is selected from Br and I Q 1a is a --COOH group or a salt thereof with a pharmacologically acceptable base Q 2a is selected from a hydrogen atom; a radical of the formula ##STR104## in which R 5 and R 6 are independently from one another selected from a hydrogen atom, a lower alkyl radical, a lower hydroxyalkyl radical, and a lower alkanoyloxy lower alkyl radical; an amino group; and a radical of the formula ##STR105## in which R 7 is selected from a lower alkyl radical, a lower hydroxyalkyl radical, and a lower alkoxy lower alkyl radical, and R 8 is selected from a hydrogen atom, a lower alkyl radical and a lower hydroxyalkyl radical; Q 3a is selected from an amino group and a radical of the formula ##STR106## in which R 9 and R 10 have the meanings given for R 7 and R 8 , respectively; -- compounds of the formula: ##STR107## in which: X is selected from Br and I, Q 1b represents a radical of the formula ##STR108## in which R 11 is a polyhydroxy lower alkyl radical and R' 11 is selected from a hydrogen atom and a lower alkyl radical, Q 2b represents a radical of the formula ##STR109## in which R 12 and R 13 have the meanings given for R 5 and R 6 , respectively, Q 3b is selected from a radical of the formula ##STR110## in which R 14 and R 15 have the meanings given for R 5 and R 6 , respectively, and a radical of the formula ##STR111## in which R 16 and R 17 have the meanings given for R 7 and R 8 , respectively; -- compounds of the formula: ##STR112## in which: X is selected from Br and I, Q 1c represents a radical of the formula --CONH--R 18 in which R 18 is selected from a sugar residue and a polyhydroxy lower alkyl radical, Q 2c represents a radical of the formula ##STR113## in which R 19 and R 20 have the meanings given for R 7 and R 8 , respectively, and is selected from a radical of the formula ##STR114## in which R 21 and R 22 have the meanings given for R 5 and R 6 , respectively, and a radical of the formula ##STR115## in which R 23 and R 24 have the meanings given for R 7 and R 8 , respectively; -- compounds of the formula: ##STR116## in which: X is selected from Br and I, Q 1d is a --COOH group or a salt thereof with a pharmacologically acceptable base, Q 2d and Q 3d are radicals which have the same meanings as Q 2a , and Q 2d may also represent a radical --CH 2 OH, Q 4d is selected from a group --NH 2 and a radical of the formula ##STR117## in which R 25 has the meaning given for R 7 and R 26 is selected from the radicals given for R 8 and a lower alkanoyl radical, Z is selected from H and OH n 1 is an integer from 1 to 5, n 2 is an integer from 0 to 6; -- compounds of the formula: ##STR118## in which: X is selected from Br and I, Q 1e and Q 3e are --COOH groups or salts thereof with pharmacologically acceptable bases Q 2e and Q 4e have the meanings given for Q 2a ; -- compounds of the formula: ##STR119## in which: X is selected from Br and I, Q 1f is a --COOH group or a salt thereof with a pharmacologically acceptable base, Q 2f , Q 3f , Q 4f , Q 5f and Q 6f have the meanings given for Q 2a , Z is selected from H and OH, and n is an integer from 0 to 6; -- compounds of the formula: ##STR120## in which: X is selected from Br and I, Q 1g represents a radical of the formula ##STR121## in which R 27 is a polyhydroxy lower alkyl radical and R' 27 is selected from a hydrogen atom and a lower alkyl radical, Q 2g and Q 3g represent independently from one another a radical selected from a radical ##STR122## in which R 28 and R 29 are independently selected from a hydrogen atom, a lower alkyl radical, a lower hydroxyalkyl radical, and a lower alkanoyloxy lower alkyl radical; an amino group; and a radical of the formula ##STR123## in which R 30 is selected from a lower alkyl radical, a lower hydroxyalkyl radical and a lower alkoxy lower alkyl radical, and R 31 is selected from a hydrogen atom, a lower alkyl radical and a lower hydroxyalkyl radical, Z 1 and Z 2 are independently from one another selected from H and OH, n 1 and n 2 represent independently from one another an integer from 0 to 6, and n 3 represents an integer from 0 to 4; -- compounds of the formula: ##STR124## in which: X is selected from Br and I, Q 1h , Q 2h and Q 3h are independently from one another selected from a --COOH group, a --COOH group converted to a salt with a pharmacologically acceptable base, and a group of the formula ##STR125## in which R 32 and R 33 represent independently from one another a radical selected from a hydrogen atom, a lower alkyl radical, a lower hydroxyalkyl radical, and a lower alkanoyloxy lower alkyl radical.
Claim 5
Dependent Claim 25 words
X-ray contrast media as claimed in claim 3, which consist essentially of an aqueous solution of a mixture of iodobenzene compounds and of bromobenzene compounds.

References Cited (Backward Citations)

US1870203A Cited
US2580459A Cited
US2524827A Cited
US2711424A Cited
US2813118A Cited
US3076024A Cited
US2890244A Cited
US3009952A Cited
US3290366A Cited
US4014986A Cited
US4073879A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-10-02 1988-04-02 1988-10-02 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-10-02 1992-04-02 1992-10-02 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-10-02 1996-04-02 1996-10-02 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag